Answers are grounded in this paper and cite their sources.
Advances in Hodgkin lymphoma (HL) treatment have dramatically improved prognosis, with 5-year relative survival now over 80% in the United States (US) and Europe. However, subsequent malignancies, often occurring as late adverse effects of treatment, are a leading cause of morbidity and mortality
No takes yet. Share an insight, caveat, or question.
Morton et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: